Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT01690143
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸UAB, Birmingham, Alabama, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT01659658
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01658904
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01653418
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
- Conditions
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT01652092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT01626092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01625351
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
NK Cells in Cord Blood Transplantation
- Conditions
- Acute Lymphoblastic Leukemia in RemissionMyelodysplastic SyndromeRecurrent Acute Lymphoblastic LeukemiaRecurrent Non-Hodgkin LymphomaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDS Stage III Plasma Cell MyelomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage III Plasma Cell MyelomaAcute Biphenotypic LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: Fludarabine PhosphateDrug: CyclophosphamideOther: Laboratory Biomarker AnalysisDrug: LenalidomideDrug: MelphalanDrug: Mycophenolate MofetilBiological: Natural Killer Cell TherapyBiological: RituximabDrug: TacrolimusProcedure: Umbilical Cord Blood TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01619761
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 1
- Registration Number
- NCT01617213
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 19
- Registration Number
- NCT01605032
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸NYU Cancer Institute, New York, New York, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.